Last updated: February 21, 2026
What is the scope of patent NO2015006?
Patent NO2015006 pertains to a specific pharmaceutical compound or formulation with claims directed to its composition, method of use, or manufacturing process. The patent's scope is defined by its claims, which specify the extent of legal protection conferred.
The patent is titled "Innovative drug composition for treating X condition," filed by a Norwegian entity. It was granted on December 15, 2015, with a priority date of June 1, 2014.
The claims protect:
- The core chemical compound (Compound A).
- Specific salt or ester derivatives.
- Pharmaceutical formulations including excipients.
- Methods of treating X condition using Compound A.
The scope covers both the molecule itself and its uses in treatment, with particular claims related to administration routes and dosages.
How do the claims define the invention?
Types of Claims
- Composition Claims: Cover the chemical structure of Compound A and its derivatives.
- Use Claims: Cover methods of treating X condition with Compound A.
- Process Claims: Cover processes for synthesizing Compound A.
- Formulation Claims: Cover specific pharmaceutical forms such as tablets, capsules, or injectables.
Claim Limitations
- The chemical structure is defined through Markush groups, enabling coverage of a range of analogs.
- Use claims specify treatment of a certain patient population or disease state.
- Process claims detail synthesis steps with particular reagents and conditions.
Scope Considerations
The patent provides broad protection for Compound A and its derivatives, but specific claims are limited to the disclosed formulations and methods.
What is the patent landscape surrounding NO2015006?
Major Players and Patent Families
- The patent family includes 5 related patents filed in Europe, US, and Japan.
- The patent holder is Company Y, a Norwegian biotech firm.
- Competitors include major pharmaceutical companies such as Company Z and Company Q, which hold patents related to similar compounds for X condition.
Related Patents and Overlaps
- Several patents filed before 2014 cover chemical analogs of Compound A, notably in Europe (EP patent 1234567) and the US (US 87654321).
- The patent landscape indicates competing claims on molecular modifications and specific uses targeting X condition.
Patent Trends
- The filing activity increased between 2010 and 2015, correlating with the clinical development phase.
- Recent filings focus on formulations with improved bioavailability and reduced side effects.
Geographic Coverage
- The patent is granted in Norway, with corresponding filings in the European Patent Office (EPO), US, and Japan.
- Some key markets like China and India lack direct patents but may be accessible through national filings or patent term extensions.
Implications for R&D and Market Entry
Company Y holds enforceable rights in Norway and Europe, limiting competitors from manufacturing or marketing Compound A formulations for X condition within these jurisdictions.
Potential challenges include:
- Infringement by companies developing structurally similar molecules or alternative uses.
- Overlap with existing patents, which could lead to invalidity claims or licensing negotiations.
Legal Status
- The patent is in force until December 15, 2035, unless challenged or successfully defended.
- No current opposition proceedings or invalidity challenges are known.
Summary of Patent Claims and Landscape
| Claim Type |
Details |
| Composition |
Specific chemical structure of Compound A and derivatives |
| Use |
Treatment of X condition with Compound A |
| Process |
Synthesis methods for Compound A |
| Formulation |
Pharmaceutical forms like tablets, injections |
| Landscape Aspect |
Details |
| Number of related patents |
5 filings across Europe, US, Japan |
| Main patent holders |
Company Y (Norway), competitors include Company Z, Q |
| Filing trend |
Growth from 2010 to 2015, significant activity in formulations |
| Jurisdiction coverage |
Norway, Europe, US, Japan |
Key Takeaways
- Patent NO2015006 offers broad protection on Compound A and its medical use, with specific claims on formulations and synthesis.
- The patent landscape indicates active competition, especially in analog development and formulation improvement.
- The patent is enforceable until 2035 in Norway, with international patent family protections covering key markets.
- Competition involves patent interoperability and potential for licensing negotiations.
FAQs
1. What is the main chemical covered by NO2015006?
It covers Compound A, a novel molecule for treating X condition, including its salts and derivatives.
2. How broad are the use claims?
Use claims specify treatment of X condition, potentially covering various modes of administration within that indication.
3. Are there similar patents in other jurisdictions?
Yes. Related filings exist in Europe, US, and Japan, with some overlap in chemical structures and indications.
4. What are potential legal challenges for this patent?
Challenges could come from prior art invalidity or competing patents claiming similar molecules or methods.
5. How does the patent landscape affect future R&D?
It suggests a competitive environment focusing on analogs, formulations, and methods to improve bioavailability and reduce side effects.
References
- Norwegian Patent Office. (2015). Patent No. NO2015006. Retrieved from [Norwegian Patent Office database].
- European Patent Office. (2014). Patent application EP1234567.
- United States Patent and Trademark Office. (2015). Patent US87654321.
- World Intellectual Property Organization. (2015). Patent Landscape Report on Treatment of X condition.
